HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ganesh Shanmugam Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shanmugam, G. Search for Related Content PubMed PubMed Citation Articles by Shanmugam, G. Related Collections Cardiac - pharmacology Cardiac - other Coronary disease

Eur J Cardiothorac Surg 2005;28:546-550
© 2005 Elsevier Science NL

Review

Tirofiban and emergency coronary surgery

Department of Cardiac Surgery, Royal Hospital for Sick Children, Dalnair Street, Glasgow G3 8SJ, UK

Received 10 May 2005; received in revised form 28 June 2005; accepted 18 July 2005.

^* Corresponding author. Tel.: +44 0141 201 0264. (Email: sgunpat{at}hotmail.com).

The final common pathway of platelet aggregation leading to coronary thrombosis involves cross-linking of platelet receptor glycoprotein IIb–IIIa by primarily fibrinogen. Glycoprotein IIb–IIIa antagonists are being increasingly used as adjunctive therapy during percutaneous coronary intevention, and have shown to reduce the risk of death and myocardial infarction. However, a proportion of these patients continue to remain ischemic and present for emergency coronary grafting. The profound platelet inhibition in these patients enhances the already heightened risk of post-operative bleeding. With the recent approval of tirofiban for patients with acute coronary syndromes, the number of patients receiving tirofiban who subsequently undergo coronary artery bypass grafting is expected to increase substantially. Little clinical data exist, on patients who require immediate coronary artery grafting after receiving tirofiban. This article reviews the evidence for bleeding following tirofiban, discusses the relevant mechanism of action and pharmacodynamics, and analyses the strategies available in patients who need emergency coronary artery grafting after tirofiban.

Key Words: Tirofiban • Coronary artery bypass grafting